Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
55.50
-1.57-2.75%
TA
Loading chart...
Snapshot
| Index | - | P/E | 119.35 | EPS (ttm) | 0.47 | Insider Own | 44.54% | Shs Outstand | 27.39M | Perf Week | -2.77% |
| Market Cap | 1.52B | Forward P/E | 26.43 | EPS next Y | 2.10 | Insider Trans | -4.92% | Shs Float | 21.05M | Perf Month | -9.73% |
| Enterprise Value | 1.52B | PEG | 0.16 | EPS next Q | 0.34 | Inst Own | - | Short Float | 6.40% | Perf Quarter | 70.87% |
| Income | 12.62M | P/S | 14.40 | EPS this Y | 186.18% | Inst Trans | - | Short Ratio | 2.48 | Perf Half Y | 167.21% |
| Sales | 105.60M | P/B | 32.93 | EPS next Y | 93.10% | ROA | 10.96% | Short Interest | 1.35M | Perf YTD | 228.21% |
| Book/sh | - | P/C | 101.36 | EPS next 5Y | 58.96% | ROE | 40.13% | 52W High | 66.37 -16.38% | Perf Year | 213.91% |
| Cash/sh | - | P/FCF | 103.20 | EPS past 3/5Y | - | ROIC | 20.41% | 52W Low | 14.27 288.93% | Perf 3Y | 967.31% |
| Dividend Est. | - | EV/EBITDA | 82.01 | Sales past 3/5Y | 56.18% - | Gross Margin | 57.87% | Volatility | 3.97% 4.57% | Perf 5Y | 1007.78% |
| Dividend TTM | - | EV/Sales | 14.42 | EPS Y/Y TTM | 353.33% | Oper. Margin | 15.44% | ATR (14) | 2.89 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.30 | Sales Y/Y TTM | 169.23% | Profit Margin | 12.02% | RSI (14) | 48.31 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.52 | EPS Q/Q | 520.00% | SMA20 | -6.86% | Beta | 0.89 | Target Price | 66.67 |
| Payout | 0.00% | Debt/Eq | 0.62 | Sales Q/Q | 100.00% | SMA50 | 7.99% | Rel Volume | 1.53 | Prev Close | 57.07 |
| Employees | 44 | LT Debt/Eq | 0.85 | Earnings | Nov 05 | SMA200 | 84.29% | Avg Volume | 564.24K | Price | 55.50 |
| IPO Date | Nov 14, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 121.29% 38.67% | Net Debt/EBITDA | 0.12 | Volume | 864,811 | Change | -2.75% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-14-26 | Reiterated | Canaccord Genuity | Buy | $60 → $68 |
| Aug-14-26 | Reiterated | HC Wainwright & Co. | Buy | $65 → $70 |
| Aug-11-26 | Reiterated | HC Wainwright & Co. | Buy | $57 → $65 |
| Jul-28-26 | Reiterated | Craig-Hallum | Buy | $15 → $62 |
| Jul-16-26 | Initiated | Canaccord | Buy | $60 |
| May-15-26 | Reiterated | HC Wainwright & Co. | Buy | $35 → $57 |
| May-29-25 | Reiterated | HC Wainwright & Co. | Buy | $11 → $35 |
| Oct-28-24 | Reiterated | Craig-Hallum | Buy | $8.00 → $15 |
| Oct-04-24 | Reiterated | HC Wainwright & Co. | Buy | $9.00 → $11 |
| May-06-24 | Initiated | Craig-Hallum | Buy | $8.00 |
Latest News· Times ET
Sep-01-26
Sep-01-2611:50PM
Aug-31-26
Aug-31-2612:21AM
Aug-30-26
Aug-30-2612:30AM
Aug-27-26
Aug-27-2611:59PM
03:38AM
02:50AM
Aug-21-26
Aug-21-2607:02AM
Aug-16-26
Aug-16-2610:41PM
Aug-14-26
07:36AM
Aug-13-26
04:04PM
Eton Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
12:05PM
Eton Pharmaceuticals Reports Second Quarter 2026 Financial Resultsglobenewswire.com
Company
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 105 | 80 | 39 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 45 | 37 | 16 | — | — | — | — | — | — | |
| Gross Profit | 61 | 43 | 23 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 39 | 36 | 23 | — | — | — | — | — | — | |
| Research and Development | 6 | 8 | 3 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | -1 | 0 | — | — | — | — | — | — | |
| Operating Income | 16 | 0 | -3 | — | — | — | — | — | — | |
| Interest Expense | 2 | 5 | 2 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -1 | 0 | 1 | — | — | — | — | — | — | |
| Net Income Before Taxes | 13 | -5 | -4 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | 13 | -5 | -4 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 13 | -5 | -4 | — | — | — | — | — | — | |
| Net Income | 13 | -5 | -4 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.47 | -0.17 | -0.15 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.47 | -0.17 | -0.15 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.38 | -0.17 | -0.15 | — | — | — | — | — | — | |
| EBITDA | 19 | 4 | -1 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 146.05 | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 14.80 | 5.71 | 8.88 | — | — | — | — | — | — | |
| Gross Margin | 58.10 | 53.75 | 58.97 | — | — | — | — | — | — | |
| Operating Margin | 15.24 | 0.00 | -7.69 | — | — | — | — | — | — | |
| Net Margin | 12.38 | -6.25 | -10.26 | — | — | — | — | — | — | |
| Shares Outstanding | 28 | 27 | 26 | — | — | — | — | — | — | |
| Market Capitalization | 1,554 | 457 | 346 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| MAIER PAUL V | Director | Aug 28 '26 | Option Exercise | 4.96 | 75,000 | 371,750 | 109,745 | Aug 31 |
| MAIER PAUL V | Director | Aug 28 '26 | Sale | 59.07 | 50,000 | 2,953,573 | 59,745 | Aug 28 |
| Krempa David | Chief Business Officer | Aug 24 '26 | Option Exercise | 7.31 | 25,000 | 182,750 | 62,025 | Aug 24 |
| Krempa David | Chief Business Officer | Aug 24 '26 | Sale | 65.07 | 25,000 | 1,626,750 | 37,025 | Aug 24 |
| BRYNJELSEN SEAN | President & CEO | Aug 20 '26 | Sale | 60.70 | 91,022 | 5,525,301 | 961,194 | Aug 20 |
| BRYNJELSEN SEAN | President & CEO | Aug 19 '26 | Sale | 62.65 | 8,978 | 562,472 | 1,052,216 | Aug 20 |
| Opaleye Management Inc. | 10% Owner | Jul 14 '26 | Sale | 37.54 | 28,315 | 1,063,033 | 40,000 | Jul 16 |
| BRYNJELSEN SEAN | President & CEO | Jul 14 '26 | Option Exercise | 1.37 | 400,000 | 548,000 | 1,061,194 | Jul 14 |
| BRYNJELSEN SEAN | President & CEO | Jul 12 '26 | Option Exercise | 0.00 | 27,500 | 0 | 861,194 | Jul 14 |
| Krempa David | Chief Business Officer | Jul 12 '26 | Option Exercise | 0.00 | 10,000 | 0 | 37,025 | Jul 13 |
| Opaleye Management Inc. | 10% Owner | Jul 07 '26 | Sale | 38.37 | 26,685 | 1,023,978 | 53,315 | Jul 07 |
| Opaleye Management Inc. | 10% Owner | Jul 06 '26 | Sale | 38.00 | 10,000 | 380,000 | 2,700,000 | Jul 07 |
| Opaleye Management Inc. | 10% Owner | Jul 02 '26 | Sale | 37.39 | 90,000 | 3,364,660 | 60,000 | Jul 07 |
| Adams Jennifer McKie | Director | Jun 17 '26 | Option Exercise | 3.78 | 50,000 | 189,000 | 50,000 | Jun 17 |
| Adams Jennifer McKie | Director | Jun 17 '26 | Sale | 32.48 | 50,000 | 1,623,795 | 0 | Jun 17 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.